▾ Celiprolol – a better beta blocker?

1992 ◽  
Vol 30 (9) ◽  
pp. 35-36

Celiprolol (Celectol – Rhoône Poulenc Rorer) is a new cardioselective β-blocker and vasodilator, intended for once daily treatment of mild to moderate hypertension. The manufacturer claims that “it improves the overall cardiovascular risk profile” and gives hypertensive patients “a better quality of life than can be expected from conventional β-blocker treatment”. We examine these claims.

2003 ◽  
Vol 163 (20) ◽  
pp. 2460 ◽  
Author(s):  
Martha L. Daviglus ◽  
Kiang Liu ◽  
Amber Pirzada ◽  
Lijing L. Yan ◽  
Daniel B. Garside ◽  
...  

2022 ◽  
Vol Volume 15 ◽  
pp. 545-554
Author(s):  
Bastian Schrader ◽  
Anna-Maria Bünker ◽  
Charis Conradi ◽  
Stephan Lüders ◽  
Bernhard Vaske ◽  
...  

2004 ◽  
Vol 4 (6) ◽  
pp. 937-945 ◽  
Author(s):  
Marika A. Artz ◽  
Johannes M. M. Boots ◽  
Gerry Ligtenberg ◽  
Joke I. Roodnat ◽  
Maarten H. L. Christiaans ◽  
...  

2019 ◽  
Vol 18 (6) ◽  
pp. 492-500 ◽  
Author(s):  
Ana M Martínez-Díaz ◽  
Antonio Palazón-Bru ◽  
David M Folgado-de la Rosa ◽  
Dolores Ramírez-Prado ◽  
Patricia Llópez-Espinós ◽  
...  

Background: Cardiovascular risk scales in hypertensive populations have limitations for clinical practice. Aims: To develop and internally validate a predictive model to estimate one-year cardiovascular risk for hypertensive patients admitted to hospital. Methods: Cohort study of 303 hypertensive patients admitted through the Emergency Department in a Spanish region in 2015–2017. The main variable was the onset of cardiovascular disease during follow-up. The secondary variables were: gender, age, educational level, family history of cardiovascular disease, Charlson score and its individual conditions, living alone, quality of life, smoking, blood pressure, physical activity and adherence to the Mediterranean diet. A Cox regression model was constructed to predict cardiovascular disease one year after admission. This was then adapted to a points system, externally validated by bootstrapping (discrimination and calibration) and implemented in a mobile application for Android. Results: A total of 93 patients developed cardiovascular disease (30.7%) over a mean period of 1.68 years. The predictors in the points system were: gender, age, myocardial infarction, heart failure, peripheral arterial disease and daily activity (quality of life). The internal validation by bootstrapping was satisfactory. Conclusion: A novel points system was developed to predict short-term cardiovascular disease in hypertensive patients after hospital admission. External validation studies are needed to corroborate the results obtained.


Sign in / Sign up

Export Citation Format

Share Document